Table 2.
HPV vaccine dose adherence rate among 111,286 commercially insured females who completed the 3-dose HPV vaccine series.
| Characteristics | HPV vaccine dose adherence N, % |
Multivariable logistic regression model |
|||
|---|---|---|---|---|---|
| Adjusted OR | 95% Confidence intervals | P-value | |||
| Age group at the 1st dose of HPV vaccination | |||||
| 9–10 (N=2,416) | 1,437, 59.5% | 0.75 | 0.68 | 0.83 | <.0001 |
| 11–12 (N=27,041) | 16,233, 60.0% | 0.79 | 0.75 | 0.84 | <.0001 |
| 13–15 (N=32,790) | 19,675, 60.0% | 0.74 | 0.70 | 0.78 | <.0001 |
| 16–17 (N=18,741) | 11,426,61.0% | 0.69 | 0.65 | 0.73 | <.0001 |
| 18–21 (N=17,667) | 11,164,63.2% | 0.64 | 0.61 | 0.68 | <.0001 |
| 22–26 (N=12,631) | 9,462, 74.9% | Ref. | |||
| US census region | |||||
| Northeast (N=19,227) | 12,257, 63.8% | 1.12 | 1.08 | 1.17 | <.0001 |
| South (N=40,307) | 25,406, 63.0% | 1.02 | 0.98 | 1.05 | 0.2933 |
| West (N=19,570) | 11,800, 60.3% | 0.94 | 0.91 | 0.98 | 0.0030 |
| North Central (N=32,182) | 19,934, 61.2% | Ref. | |||
| Residence | |||||
| Urban (MSA) (N=98,879) | 61,218, 61.9% | 0.87 | 0.84 | 0.91 | <.0001 |
| Rural (non-MSA) (N=12,407) | 4,228, 65.9% | Ref. | |||
| Health insurance plan | |||||
| CDHP (N=5,291) | 3,212, 60.7% | 1.01 | 0.95 | 1.08 | 0.7528 |
| Comprehensive (N=1,053) | 680, 64.6% | 1.14 | 0.99 | 1.30 | 0.0513 |
| EPO (N=2,183) | 1,326, 60.7% | 1.02 | 0.92 | 1.11 | 0.7423 |
| HDHP (N=2,545) | 1,581, 62.1% | 1.07 | 0.98 | 1.17 | 0.1263 |
| POS (N=8,258) | 5,114, 61.9% | 1.02 | 0.96 | 1.07 | 0.5530 |
| POS capitation (N=815) | 527, 64.7% | 1.09 | 0.94 | 1.27 | 0.2434 |
| PPO (N=71,703) | 45,030, 62.8% | 1.05 | 1.02 | 1.09 | 0.0040 |
| HMO (N=17,110) | 10,469, 61.2% | Ref. | |||
| Type of provider who administered the 1st dose | |||||
| Pediatric (N=46,344) | 26,243, 56.6% | 0.74 | 0.72 | 0.77 | <.0001 |
| OB/GYN (N=18,006) | 13,207, 73.4% | 1.41 | 1.34 | 1.48 | <.0001 |
| Others (N=31,101) | 15,755, 63.2% | 0.96 | 0.92 | 0.99 | 0.0402 |
| Primary care (N=15,835) | 10,203, 64.4% | Ref. | |||
| Quarter of the year at the 1st dose | |||||
| Jan–Mar (N=25,894) | 17,429, 67.3% | 1.30 | 1.25 | 1.36 | <.0001 |
| Apr–Jun (N=31,671) | 20,831, 65.8% | 1.26 | 1.21 | 1.31 | <.0001 |
| Jul–Sep (N=36,423) | 20,682, 56.8% | 0.89 | 0.86 | 0.92 | <.0001 |
| Oct–Dec (N=17,298) | 10,455, 60.4% | Ref. | |||
| Flu shot | |||||
| Yes (N=46,847) | 27,686, 59.1% | 0.92 | 0.90 | 0.95 | <.0001 |
| No (N=64,439) | 41,711, 64.7% | Ref. | |||
Abbreviations: HPV: human papillomavirus; MSA: Metropolitan Statistical Area; CDHP: consumer-driven health plan; EPO: Exclusive provider organizations; HDHP: high-deductible health plan; POS: point of service; PPO: Preferred provider organizations; HMO: Health maintenance organizations; OB/GYN: obstetrics and gynecology; OR: odds ratio; CI: confidence interval.